Verrica Pharmaceuticals Inc. (VRCA) Misses Q2 EPS by 3c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $180 thousand versus the consensus estimate of $257.6 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Community Banks sells equipment finance unit for $1.9 billion
• Sharon AI secures six-year compute deal with NVIDIA for Australia deployment